Truist lowered the firm’s price target on Amrize (AMRZ) to $65 from $75 and keeps a Buy rating on the shares after its Q1 earnings miss. The Building Envelope segment saw substantial pressure on residential demand, coupled with declines in commercial, and while residential could recover with storms, the firm sees a modestly weak year in commercial in 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ:
- Amrize upgraded to Buy from Hold at Vertical Research
- Amrize reports Q1 EPS (16c), consensus (14c)
- Amrize reaffirms FY26 revenue view $12.29B-$12.52B, consensus $12.42B
- Amrize lifts Q1 revenue, boosts shareholder returns and reaffirms 2026 outlook
- Amrize shareholders approve all proposals at General Meeting